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ABSTRACT 
During an inflammatory response, lymphocyte recruitment into tissue must be tightly 
controlled because dysregulated trafficking contributes to the pathogenesis of chronic 
disease. Here we show that during inflammation and in response to adiponectin, B cells 
tonically inhibit T cell trafficking by secreting a peptide (PEPITEM) proteolytically 
derived from 14.3.3.ζδ protein. PEPITEM binds cadherin-15 on endothelial cells, 
promoting synthesis and release of sphingosine-1 phosphate, which inhibits trafficking 
of T cells without affecting recruitment of other leukocytes. Expression of adiponectin 
receptors on B cells and adiponectin induced PEPITEM secretion wanes with age, 
implying immune senescence of the pathway. Additionally, these changes are evident in 
individuals with type-1-diabetes or rheumatoid arthritis, and circulating PEPITEM in 
patient serum is reduced compared to healthy age matched donors. In both diseases, 
tonic inhibition of T cell trafficking across inflamed endothelium is lost. Importantly, 
control of patient T cell trafficking is re-established by exogenous PEPITEM. 
Moreover, in animal models of peritonitis, hepatic I/R injury, Salmonella infection, 
Uveitis and Sjögren’s Syndrome, PEPITEM could reduce T cell recruitment into 
inflamed tissues. 
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INTRODUCTION 
In vertebrates, a lymphocyte (T cell and B cell) based adaptive immune system has 
evolved to augment innate immunity. Adaptive responses require lymphocyte trafficking 
between the bone marrow, lymphoid organs and peripheral tissues using blood as a vehicle 
for dispersal1. Understanding of the trafficking process is still incomplete. However, 
unregulated T cell recruitment during inflammation is pathogenic and contributes to chronic 
disease2, 3. Here we reveal the function of a homeostatic pathway, which imposes a tonic 
inhibition on T cell trafficking during inflammation. Identification of this pathway arose 
through studies on the circulating adipokine, adiponectin. Adiponectin affects both metabolic 
and immune pathways4−7, including the recruitment of leukocytes during an inflammatory 
response6, and plasma concentrations are low in a number of chronic diseases, including 
diabetes4. For the first time we tested the hypothesis that adiponectin might regulate 
lymphocyte trafficking and that changes in adiponectin function might contribute to 
pathogenic lymphocyte recruitment in chronic inflammatory and autoimmune diseases.  
We started by observing lymphocyte trafficking in vitro across isolated human 
endothelial cells, which are the gatekeepers to the tissues for circulating leukocytes. To enter 
inflamed tissue, T cells migrate through endothelial cells lining the post-capillary venules 8, 9, 
and this has been modelled both in vitro and in vivo10-15. Thus, memory T cells moving 
rapidly in the flowing blood are preferentially recruited by endothelial cells activated by 
cytokines (e.g. TNF-α and/or IFN-γ). Tethering from flow and rolling adhesion are supported 
by E-selectin and VCAM-116, while integrin mediated stable adhesion and migration are 
supported by sequential signals from chemokines and prostaglandin-D217−23. Here we show 
that in the presence of adiponectin, B cells recruited to the endothelial cell surface during 
inflammation reduce the efficiency of memory T cell migration by imposing a tonic 
inhibition on this process. Thus, we believe that the adaptive immune system has evolved a 
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robust strategy for regulating inappropriate or excessive activity, thereby limiting the 
possibility of establishing a chronic inflammatory response which might contribute to 
disease.  
 
RESULTS 
Adiponectin regulates T cell migration  
In vitro, adiponectin dose-dependently inhibited the TNF-α and IFN-γ  induced trans-
endothelial migration of human peripheral blood lymphocytes (PBL) with an EC50 of 2.6 nM 
(0.94 µg/ml) (Fig. 1a, Supplementary Fig. 1a), with the most marked effects seen at 
physiological circulating levels observed in healthy humans (5−15 μg/ml). Although 
migration was reduced so that more cells were firmly adherent to the apical surface of the 
endothelium (Supplementary Fig. 1b), the number of lymphocytes recruited was unaffected 
by adiponectin (Supplementary Fig. 1c). The effects of adiponectin on PBL migration were 
seen in both a static system (Fig. 1a), and under conditions of flow (Fig. 1b), and were 
evident on human umbilical vein endothelial cells (HUVEC), or human dermal micro-
vascular endothelial cells (HDMEC) (Fig. 1c). The majority of transmigrating PBL were 
CD3+CD45RO+memory T cells, as expected for this model (17 and data not shown). 
Adiponectin did not alter the expression and/or function of lymphocyte integrins (α4β1 and 
αLβ2), the CXCR3 chemokine receptor, or the PGD2 receptor (DP-2) on PBL 
(Supplementary Fig. 1d). Moreover, chemotactic responses to CXCL12, CXCL10, or PGD2 
were unaltered by adiponectin (Supplementary Fig. 1e). Less than 5% of T cells (CD3+ 
cells), including memory and naïve subsets, expressed adiponectin receptors (AdipoR1 and 
AdipoR2) (Fig. 1d-f). However, circulating B cells (CD19+ cells) expressed both receptors 
abundantly (Fig. 1d-f). We also found that endothelial cells expressed both adiponectin 
receptors (Supplementary Fig. 2). However, adiponectin did not directly target endothelial 
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cells in our system, as treated PBL are washed to remove any adiponectin prior to their 
addition to the endothelial cells. To ensure that any residual carryover of this agent did not 
influence lymphocyte recruitment, we verified that adiponectin did not modulate the gene 
expression of adhesion molecules and chemokines in TNF-α and IFN-γ stimulated 
endothelial cells (Supplementary Table 1). As T cells lack adiponectin receptors but show 
altered patterns of migration in response to adiponectin, we postulated that another 
lymphocyte population mediated the inhibition of T cell trafficking. Upon depleting B cells 
from the PBL mixture, T cells were released from the inhibitory effects of adiponectin (Fig. 
1g). Adding back purified B cells to isolated T cells could reconstitute the adiponectin-
dependent inhibition of T cell migration, and using supernatants from adiponectin stimulated 
B cells was as effective as addition of B cells themselves (Fig. 1g). The ability of B cell 
supernatants to impair T cell migration was lost when B cells were activated with adiponectin 
in the presence of an inhibitor of protein secretion, brefeldin-A (Fig. 1g). These experiments 
suggest B cells release a soluble factor in response to stimulation by adiponectin that 
regulates migration of T cells. 
 
Adiponectin induces PEPITEM secretion by B cells   
We utilized an unbiased proteomic screen to identify the agent(s) secreted by purified 
B cells following stimulation with or without adiponectin. A comparative analysis identified 
a 14 amino-acid peptide, SVTEQGAELSNEER, specific to the supernatants of adiponectin 
stimulated B cells (Fig. 2a). Comparing this to an in silico library of published and predicted 
sequences, the peptide demonstrated 100% sequence homology to a single human protein, 
and represents amino acids 28−41 of the 14.3.3 zeta delta (14.3.3.ζδ) protein, which in turn is 
a 245 amino-acid product of the YWHAZ gene (Fig. 2b).  
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Proteolytic release of the peptide from the parent protein was confirmed after a tryptic 
digestion of recombinant 14.3.3.ζδ generated the same 14 amino-acid product 
(Supplementary Table 2). A time course of the 14.3.3.ζδ derived peptide secretion from 
adiponectin stimulated B cells showed rapid and sustained release (Supplementary Fig. 3a). 
A synthetic peptide exhibited an identical mass:charge (m/z) ratio to that of the native peptide 
(m/z=774.88), suggesting the B cell derived product was not subject to post-translational 
modification prior to secretion (Supplementary Fig. 3b, c). Synthetic peptide showed a 
dose-dependent inhibitory effect on the trafficking of PBL across TNF-α and IFN-γ 
stimulated endothelial cells in vitro (Fig. 2c), with an EC50 of 19 pM (28 pg/ml) 
(Supplementary Fig. 4a). A similar response was observed in the absence of bovine serum 
albumin, which removed any source of arachidonic acid that might be used to generate 
bioactive eicosanoids such as PGD2, which are known to regulate T cell trafficking23 
(Supplementary Fig. 4b). Like adiponectin, the peptide had no effect on the number of 
lymphocytes adherent to the endothelial cells (Supplementary Fig. 4c), but it increased the 
number of surface adherent cells, as migration through the monolayer was inhibited 
(Supplementary Fig. 4d). A scrambled peptide, containing the same amino acids in random 
order, or other peptides of unrelated sequence but with known biological activity (proinsulin 
chain A peptide and tetanus toxoid peptide), had no effect on T cell migration (Fig. 2c). As 
the peptide inhibited T cell migration we named it PEPtide Inhibitor of Trans-Endothelial 
Migration; PEPITEM. PEPITEM specifically inhibited the migration of CD4+ and CD8+ 
memory T cells, without affecting transmigration of neutrophils or monocytes (Fig. 2d), nor 
the total adhesion of any leukocyte subset (Supplementary Table 3 and 4 for adiponectin). 
In addition, PEPITEM inhibited T cell transmigration on both HDMEC and HUVEC 
(Supplementary Fig. 4e). PEPITEM was ineffective if PBL were pre-treated, and only had 
inhibitory effects when pre-incubated on endothelial cells, implying that PEPITEM operated 
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by stimulating a receptor on these cells (Supplementary Fig. 4f). When we fractionated B 
cells into their subsets, we found that plasma cells (CD38+++IgD−IgM−CD27−) were able to 
secrete higher quantities of PEPITEM compared to naïve (CD38+IgD+IgM+) or memory 
(CD38−IgD−IgM−CD27−) B cells following incubation with adiponectin (Supplementary 
Table 5). There was also an enrichment of plasma cells on cytokine stimulated endothelial 
cells (Supplementary Fig. 4g). These data imply a dominant role for circulating plasma cells 
in the regulation of memory T cell trafficking. 
 
The endothelial cell receptor for PEPITEM is Cadherin-15  
 To identify a PEPITEM receptor on endothelial cells, we utilized PEPITEM with a 
biotin conjugate on the N-terminus as ‘bait’ to ‘fish’ for binding partners on the endothelial 
cell surface. This peptide showed full efficacy in a functional migration assay 
(Supplementary Fig. 5a). PEPITEM-bound molecules were co-immobilized on neutravidin 
columns after endothelial cell lysis. Proteins eluted from the neutravidin columns were 
subject to analysis by mass-spectrometry for identification. This strategy yielded a candidate 
with a strong statistical score (>30), cadherin-15 (CDH15; M-cadherin). CDH15 was 
efficiently knocked down in endothelial cells by specific siRNA oligomers, but not by control 
sequences (Fig. 2e, g and Supplementary Fig. 5b). Silencing of CDH15 did not alter the 
baseline efficiency of T cell migration across the endothelium (Supplementary Fig. 5c). 
However, it did release T cells from the inhibitory effects of PEPITEM (Fig. 2f). Binding 
data indicates that PEPITEM is able to bind recombinant CDH15 in a Biacore assay 
(KD=108.9 µM) (Supplementary Fig. 5d).  
CDH15 has not previously been described in endothelial cells, and here we show that 
mRNA for CDH15 is endogenously expressed, as well as being up-regulated when 
endothelial cells are stimulated with inflammatory cytokines (Fig. 2e). In addition, CDH15 
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expression and up-regulation by cytokines in HDMEC was detected at a protein level using 
western blotting (Fig. 2g). Confocal microscopy also showed expression in HDMEC and 
skeletal muscle cells (SkMC, used as a positive control) using fluorescently labelled reagents, 
and staining was reduced following siRNA-mediated silencing of CDH15, demonstrating the 
specificity of the antibody (Fig. 2g, h and Supplementary Fig. 5b). 
 
Endothelial cell Sphingosine-1-phosphate impairs migration   
 Sphingosine-1-phosphate (S1P) is a biologically active sphingolipid generated in the 
cytosol from sphingosine, which is phosphorylated by the sphingosine kinases (SPHK), 
SPKH1 or SPHK219. The endothelial cell transporter, spinster homolog 2 (SPNS2), is also 
necessary for translocation of S1P into extra-cellular fluid24−26. S1P plays an important 
regulatory role in the movement of T cells from inflamed tissue to afferent lymphatics27 and 
for T cell egress from secondary lymphoid organs28−31. Here we found the S1P receptor 
antagonist, W146 (trifluoroacetate salt), released T cells from the inhibitory effects of both 
adiponectin and PEPITEM (Fig. 3a, b). Moreover, the effects of adiponectin and PEPITEM 
on T cell migration could be mimicked dose-dependently, when exogenous S1P was added to 
purified T cells (Fig. 3c). We confirmed that S1P was of endothelial origin by pre-treating 
endothelial cells with the SPHK1 inhibitor (2,2-dimethyl-4S-(1-oxo-2-hexadecyn-1-yl)-1,1-
dimethylester-3-oxazolidinecarboxylic acid) or the SPHK1/2 inhibitor (N,N-
Dimethylsphingosine) which abolished the ability of PEPITEM to inhibit T cell migration 
(Fig. 3d, e). In agreement with the patterns of activity of these inhibitors, we found that 
SPHK1, but not SPHK2, was highly expressed in endothelial cells but not in B cells 
(Supplementary Fig. 6a), and that mRNA for SPHK1, but not SPHK2, was increased upon 
stimulation of endothelial cells with TNF-α and IFN-γ (Fig. 3f). Knock-down of endothelial 
SPNS2 mRNA also released T cells from the inhibitory effects of PEPITEM (Fig. 3g and 
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Supplementary Fig. 6b-d). Addition of S1P to endothelial cells at a concentration equivalent 
to the total circulating concentration in plasma (≈0.2 µM)32 inhibited T cell transmigration 
efficiently (Fig. 3c). However, in the circulation S1P is bound to plasma proteins such as 
albumin and lipoproteins32, 33 which limit its availability. Published data estimates that 
biologically active S1P circulates at approximately 5 nM33, 34.  In the presence of this 
concentration of S1P, the effects of PEPITEM on migration were readily observable 
(Supplementary Fig. 6e-g). Moreover, PEPITEM inhibition of T cell trafficking in the 
presence of 5 nM S1P could be reversed by treating endothelial cells with SPHK inhibitors or 
by SPNS2 knock-down in these cells, showing that additional and functional S1P was 
released in response to PEPITEM stimulation (Supplementary Fig. 6e-g).  
The process of T cell egress from lymph nodes into blood results in rapid S1P-
mediated internalisation of S1P-receptors (S1PR1 and S1PR4) from the surface of circulating 
T cells30, 31. Thus for S1P to be an effective mediator during T cell migration across 
endothelial cells, S1P-receptors on T cells require up-regulation. We observed a robust 
increase in the expression of S1PR1 on the cell surface of memory T cells that had been 
recruited by cytokine stimulated endothelial cells (Fig. 3h). Moreover, rapid up-regulation of 
surface S1PR1 was observed when memory T cells adherent to immobilized, recombinant 
ICAM-1, were stimulated by CXCL10 (Fig. 3i, Supplementary Fig. 7a). This mode of T 
cell activation could overide the desensitisation pathways for S1PR1, as high expression was 
maintained even in the presence of 10 μM of exogenous S1P (Supplementary Fig. 7a).  
Moreover, this was not due to the recruitment of a subset of cells with high S1PR1 
expression, as these were not evident in the isolated T cells prior to addition to the ICAM-1 
(Supplementary Fig. 7a). Thus, during the process of recruitment, chemokines presented by 
endothelial cells rapidly and sustainably induce expression of S1PR1 on memory T cells.  
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 S1P down-regulates the affinity of the T cell integrin adhesion receptor αLβ2 (LFA-1), 
reducing binding to ICAM-1 after stimulation with the chemokine CXCL10 (Fig. 3j, 
Supplementary Fig. 7b). This change in integrin function did not alter the levels of T cell 
recruitment, which is E-selectin and VLA-4 dependent, in this model of in vitro 
transmigration (17 and data not shown). However, in the presence of adiponectin (and 
therefore S1P) there was a modest increase in the number of cells rolling on the endothelial 
cell surface (Supplementary Fig. 7c). Taken together these data imply that S1P-mediated 
changes in the function of LFA-1 are able to interrupt the process of LFA-1 mediated trans-
endothelial migration.  
 
PEPITEM is functional in vivo  
 As PEPITEM is derived from B cells, we conducted a series of studies in the BALB/c 
B cell-deficient mouse35. In a model of zymosan-induced peritonitis, more T cells trafficked 
into the peritoneal cavity in B cell-deficient mice (Fig. 4a). Injection of PEPITEM during 
challenge with zymosan inhibited trafficking of T cells into the peritoneum (Fig. 4a). 
Additionally, we tested the efficacy of PEPITEM in a model of systemic bacteraemia 
upon Salmonella Typhimurium infection in the C57BL/6 B cell-deficient mouse. Salmonella 
colonizes the spleen and liver during primary infection36 where it promotes an inflammatory 
infiltrate into infectious foci. PEPITEM reduces the number of T cells resident in these 
infectious foci in Salmonella infected B cell-deficient animals (Fig. 4b), with a trend towards 
reduced T cells in PEPITEM-treated wild-type (WT) animals (Supplementary Fig. 8a, b). 
PEPITEM also abolished T cell recruitment in the hepatic sinusoids, with a concomitant 
increase in the number of free flowing T cells, after acute liver ischaemia and reperfusion 
injury in C57BL/6 WT mice, when assessed by realtime intravital microscopy (Fig. 4c, d and 
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Supplementary Fig. 8c). This observation is consistent with integrin mediated processes that 
support leukocyte tethering in the low shear environment of the hepatic sinusoids37, 38.  
In a model of endotoxin-induced (LPS) autoimmune uveitis (ocular inflammation) in 
C57BL/6 WT mice, administration of PEPITEM with LPS into the eye reduced the number 
of T cells in the ocular infiltrate (Fig. 4e). PEPITEM also reduced T cell trafficking into the 
salivary glands of C57BL/6 WT mice challenged with a virally induced model of tertiary 
lymphoid organ formation, which mimics changes observed in the autoimmune rheumatic 
disease, Sjögren’s syndrome39 (Fig. 4f, g). In both uveitis and Sjögren’s syndrome models, as 
well as in the zymosan-induced peritonitis (data not shown), B cells were recruited to the 
sites of inflammation and the number of B cells recruited was not affected by PEPITEM 
(Supplementary Fig. 8d, e). In addition, in the in vivo model of acute, resolving 
inflammation (peritonitis), the recruitment patterns of F4/80 macrophages and CD11c+ cells 
were not affected at the time point used to assess T cell trafficking (Supplementary Fig. 8f, 
g). 
 
The PEPITEM pathway is impaired in disease and the elderly  
Efficacy in in vivo models of inflammation prompted us to investigate whether the 
PEPITEM pathway was compromised in individuals with the T cell driven autoimmune 
disease, type-1-diabetes (T1D) or individuals with rheumatoid arthritis. Firstly, we measured 
the expression of AdipoR1 and AdipoR2 on the circulating B cells of individuals with T1D or 
rheumatoid arthritis, comparing these to healthy age and gender matched control donors. 
(Cohort statistics in Supplementary Table 6, 7 and 8). The expression of both AdipoR1 
and AdipoR2 was reduced on B cells from individuals with T1D (Fig. 5a for % positive B 
cells and Supplementary Fig. 9a for representative intensity histograms) and with 
rheumatoid arthritis (Fig. 5b for % positive B cells and Supplementary Fig. 9a for 
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representative intensity histograms) compared to healthy controls. We observed no difference 
in the expression of CD19 on B cells and in B cell number between healthy controls and 
individuals with T1D or rheumatoid arthritis, suggesting these differences reflect changes in 
AdipoR1 and AdipoR2 expression (Supplementary Fig. 9b, c). There was a positive 
correlation between the expression of AdipoR1 and AdipoR2 on B cells with the quantity of 
PEPITEM released by B cells upon stimulation with adiponectin (Fig. 5c, d). This was the 
case for both individuals with T1D and healthy controls (AdipoR2 only), although in 
individuals with T1D only low levels of PEPITEM could be detected, which reflected the 
paucity of expression of adiponectin receptors. In addition, we were able to detect low 
concentrations of PEPITEM in serum from healthy controls and this was reduced in 
individuals with T1D (Fig. 5e).  
Decreased PEPITEM secretion by B cells released T cells from the inhibitory effects 
of adiponectin, so that there was no longer an inhibition of T cell migration in individuals 
with T1D (Fig. 5f) or those with rheumatoid arthritis (Fig. 5g). The effects of adiponectin 
could be mimicked by the addition of exogenous PEPITEM in  the ex vivo migration assay, 
using lymphocytes from individuals with T1D or rheumatoid arthritis (Fig. 5f, g), meaning 
that loss of tonic inhibition of T cell migration in these individuals could be readily replaced 
with appropriate PEPITEM treatment.  
One of the major risk factors for developing chronic inflammatory or autoimmune 
diseases is age. Thus, we analyzed the expression of AdipoR1 and AdipoR2 in healthy donors 
of different ages. There was a negative correlation between the expression of AdipoR1 and 
AdipoR2 and age (Fig. 5h, i).  
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DISCUSSION 
The processing of an immune regulatory, 14 amino-acid peptide, from an intracellular 
protein (14.3.3ζδ) with no known association to the inflammatory response has not been 
described in, nor could it have been predicted from,  any of the known pathways that regulate 
leukocyte trafficking. In fact, the functions of the 7 family members of the 14.3.3 protein 
family are diverse. For example, they are involved in regulating the function of cytosolic 
proteins which support metabolic, cell cycle, apoptotic and protein trafficking pathways40−42. 
Their importance in such homeostatic pathways is highlighted by their association with 
diseases as varied as cancer, hyper-proliferative skin disorders and Alzheimer’s disease, 
when their function is disrupted43, 44. The effects of losing the function of the PEPITEM 
pathway that we document here now allows us to add T1D and rheumatoid arthritis to the list 
of diseases in which the dysregulated function of 14.3.3 proteins plays a role.  
Here we showed that extracellular PEPITEM impaired lymphocyte trafficking by 
indirectly regulating the function of the β2-integrin, LFA-1. Interestingly, both intracellular 
14.3.3β and 14.3.3ζδ have been implicated in the regulation of adhesion dependent cellular 
functions in other contexts. For example, morphology and adhesion in dendrites, embryonic 
kidney cell lines and rat fibroblasts, are associated with the 14.3.3β dependent regulation of 
β1-integrins45−50. Moreover, 14.3.3ζδ protein in platelets regulates the function of the 
adhesion complex GPIb/IX/V, and is required for efficient recruitment of platelets to von 
Willbrand factor (VWF)51. It is also notable that S1P, the terminal mediator in the PEPITEM 
pathway, can also regulate the function of endothelial cell borne adhesion receptors52, 53 (e.g. 
VE-cadherin) which are involved in the regulated trafficking of leukocytes. Thus, although a 
role in lymphocyte trafficking is novel for 14.3.3 proteins; the regulation of adhesion 
molecules in other cells and contexts does provide a generic link between their known 
biological functions and the new role described here.   
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 In the lymph node, a process of reciprocal crosstalk between B cells and T cells is 
known to be important in establishing an antigen specific immune response54. Crosstalk 
between B cells and T cells also plays a role in the initiation of T cell mediated autoimmune 
events in T1D and rheumatoid arthritis55, 56. Indeed, ‘depletion’ of B cells by the monoclonal 
antibody rituximab has beneficial effects in these diseases57, 58. It might be assumed that such 
a B cell depletion strategy might compromise the inhibitory effects of PEPITEM on T cell 
trafficking by removing the tonic ‘brake’ on inflammation provided by this pathway 
described in detail in Figure 6. However, our data implies that this pathway is no longer 
functional in individuals with established disease. Thus, it is unlikely that the benefit of 
removing pathogenic B cells is being achieved at the expense of the protective functions of 
PEPITEM secreting B cells.  However, our observation that exogenous peptide can regain 
control of the trafficking of patient T cells raises the possibility that the PEPITEM pathway 
may present a tractable target for the development of novel therapeutic agents with which to 
treat chronic inflammatory and autoimmune diseases. In T1D or rheumatoid arthritis this 
might be achieved using the peptide itself.  However, we predict that in other disease states 
alternative aspects of this pathway may be compromised. For example, expression and 
proteolytic processing of 14.3.3.ζδ to yield mature peptide could be altered, as could the 
secretory pathways required for PEPITEM release in response to adiponectin. In endothelial 
cells, changes in the expression of cadherin-15, or the release of S1P in response to 
PEPITEM signalling could lead to inappropriate T cell trafficking. Lastly, T cells themselves 
may lose the capacity to respond to S1P by failing to upregulate S1PRs in response to 
inflammatory chemokines, or through alterations in the intrinsic signalling pathways lying 
downstream of these molecules. Many of these processes have yet to be defined 
mechanistically, for example, the identity and localisation of the protease(s) which cleave 
PEPITEM from 14.3.3. ζδ. However, with a fuller understanding of the biology of the 
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PEPITEM pathway it will be important to determine whether alterations in these other steps 
are detectable in disease. If they are, they will represent unique opportunities to develop new 
therapeutic agents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
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FIGURE LEGENDS 
Figure 1 T cell migration across endothelial cells is regulated by a soluble agent released 
from B cells stimulated with adiponectin. (a-c) The effects of adiponectin (0−15 µg/ml) on 
T cell migration across TNF-α&IFN-γ treated (a) HUVECs under static (n=3−7) or (b) flow 
conditions (n=6), or (c), HDMEC under static conditions (n=3−4). (d) Representative plots of 
Adiponectin receptor-1 and -2 (AdipoR1 and 2) expression on T cells (CD3+) and B cells 
(CD19+) measured by flow-cytometry. (e, f) Percentage of adiponectin receptor positive cells 
on lymphocyte subpopulations (measured by flow-cytometry), n=6−13. (g) Transmigration of 
T cells following B cell depletion, reconstitution of depleted preparations with B cells or B 
cell supernatant or inhibition B cell secretion by Brefeldin A (10 µg/ml), n=3−7. Data are 
from at least 3 independent experiments using 3 donors for both PBL and HUVEC/HDMEC 
and are mean±s.e.m. NS: not significant, * P≤0.05, ** P≤0.01, *** P≤0.001 by (a) linear 
regression (b-c, g) paired t-test compared to untreated (no adiponectin) control or (e, f) 
Dunnett post-test compared to B cells. 
 
Figure 2 PEPITEM inhibits T cell transmigration by binding to Cadherin-15 on 
endothelial cells. (a) MS/MS analysis of ion m/z 774.8 with the predicted sequence for 
PEPITEM, data representative of n=3. (b) Amino acid sequence of 14.3.3.ζδ with PEPITEM 
highlighted in blue. (c) The effect of PEPITEM (0−10 ng/ml), scrambled control peptide or 
irrelevant peptides (proinsulin chain A and Tetanus toxoid peptide at 10 ng/ml) on PBL 
transmigration, n=3−4. (d) The effect of PEPITEM on the transmigration of pre-sorted 
leukocyte populations. Data normalized to scrambled control peptide, n=3−6. NA= no 
adhesion. (e, f) The effects of control or cadherin-15 (CDH15) specific siRNA on (e) the 
mRNA expression of CDH15 in HDMECs (n=6) and (f) on T cell transmigration across 
HDMECs (n=6). Data normalized to (e) unstimulated or (f) untreated and no siRNA control. 
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(g-h) The effects of control or CDH15 specific siRNA on the protein expression of CDH15 
determined by (g) Western Blot or (h) confocal microscopy in HDMEC and skeletal muscle 
cells (SkMC). Scale bars: 30 µm. Data are mean±s.e.m. * P≤0.05, ** P≤0.01, *** P≤0.001 
compared to (c) no adiponectin/PEPITEM control, (d) scrambled control and (e, f) 
unstimulated control or no siRNA by Dunnett post-test. 
 
Figure 3 PEPITEM induces the S1P release from endothelial cells which inhibits T cell 
migration. (a, b) The effects of an S1PR antagonist (10 µM) on T cell migration in the 
presence or absence of (a) adiponectin (n=3−5) or (b) PEPITEM (n=3−7). (c) The effects on 
T cell transmigration of adding S1P to B cell depleted PBL n=3−6. (d, e) The effects of (d) 
SPHK1 specific inhibitor (5 µM) or (e) SPHK1/2 inhibitor (5 µM) on T cell transmigration in 
the presence of PEPITEM, n=3. (f) The expression of SPHK1 and SPHK2 mRNA in 
endothelial cells, n=7−8. (g) The effect of SPNS2 specific siRNA on T cell transmigration in 
the presence of PEPITEM, n=4.  (h, i) The expression of S1PR1 on memory T cells 
(CD3+CD45RO+) on (h) stimulated endothelial cells (n=3) and (i) on plated ICAM-1 
stimulated with CXCL10 (n=6). (j) The effects of S1P on the expression of the LFA-1 
activation epitope (KIM127) on ICAM-1 adherent memory T cells (CD3+CD45RO+) 
stimulated with CXCL10, n=4. Data are mean±s.e.m and (g-j) normalized to control. * 
P≤0.05, ** P≤0.01, *** P≤0.001 compared to untreated control by ANOVA and (a-g) 
Dunnett compared to (a-b, d-e, g) untreated control or (c) B cell depletion no adiponectin 
control or to (f) unstimulated (0) control or (j) Bonferroni post-test or (h) paired t-test on raw 
data or (i) Wilcoxon signed rank test.  
 
Figure 4 PEPITEM inhibits T cell migration in vivo. (a) T cells recruited into the 
peritoneum of BALB/c B cell-deficient  mice after induction of peritonitis using zymosan and 
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treatment with PEPITEM or scrambled peptide. All data was normalized to the number of T 
cells in BALB/c WT mice treated with zymosan, n=3−8.  (b) Mean CD3+ T cells per 
infectious foci in the liver of salmonella-infected C57BL/6 B cell-deficient mice treated with 
PEPITEM or PBS (control), n≥4. (c) Adherent CD3+ T cells per mm2 in the liver sinusoid 
following reperfusion in C57BL/6  WT mice treated with PEPITEM or scrambled peptide by 
intravital microscopy. (d) Representative pictures of CFDA-SE labelled T cells in the 
sinusoids in scrambled (top) and PEPITEM-treated mice (bottom), n=4 per group. Scale bars, 
100 µm. (e) CD3+ T cells in the ocular infiltrate of C57BL/6 WT mice treated with PBS 
(control) or PEPITEM after induction of uveitis by intravitreal injection of LPS, n=9−10. (f) 
CD3+ T cells in the salivary glands of C57BL/6 WT mice treated with scrambled peptide 
(control) or PEPITEM after induction of Sjögren’s syndrome by cannulation of salivary 
glands and injection of AdV5, n=7−8. (g) Representative pictures showing CD3+ T cells and 
CD19+ B cells in the salivary glands after scrambled peptide (left) or PEPITEM (right) 
treatment. Scale bars, 100 µm. Data are mean±s.e.m. * P≤0.05, ** P≤0.01 compared to (a) 
zymosan treated WT by Dunnett post-test or compared to (a, f) scrambled or (b, e) PBS-
treated B cell-deficient mice by unpaired t-test, or (c) two-way ANOVA. 
Figure 5 The PEPITEM pathway is compromised in T1D and rheumatoid arthritis. (a, 
b) The expression of (left) adiponectin receptor-1 or (right) adiponectin receptor-2 on B cells 
in cohorts of healthy controls (a: n=19; b: n=10) and in (a) individuals with T1D (n=29) (b) 
or rheumatoid arthritis (RA) (n=11−12). (c, d) Correlation between expression of (c) 
AdipoR1 and (d) AdipoR2 on B cells and the quantity of PEPITEM released by B cells 
following adiponectin stimulation measured by mass spectrometry in healthy controls and 
individuals with T1D, n=10 in each group. (e) Concentrations of PEPITEM in serum from 
healthy controls and individuals with T1D, n=7. (f, g) T cell transmigration in individuals (f) 
with T1D (n=9−22) or (g) rheumatoid arthritis (RA) (n=7−8) after treatment with adiponectin 
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(15 µg/ml) or PEPITEM (10 ng/ml) or scrambled peptide (10 ng/ml).  (h, i) Correlation 
between expression of (h) AdipoR1 and (i) AdipoR2 on B cells and age in healthy controls, 
n=40−41. NS= not significant. Data are mean±s.e.m. * P≤0.05, ** P≤0.01, *** P≤0.001 
compared to (a) healthy control by Mann-Whitney test or (b, e) unpaired t-test or (f, g) paired 
t-test for healthy controls and (f, g) ANOVA and Dunnett post-test for individuals with T1D 
and rheumatoid arthritis (c, d, h, i) by linear regression. 
Figure 6 Schematic depicting B cell-mediated regulation of T cell trafficking during 
inflammation. (1) Endothelial cells stimulated with pro-inflammatory cytokines such as 
TNF-α and IFN-γ recruit flowing T cells in the blood. (2) β1- and β2-integrins are activated 
by chemokine signals from CXCL9−11 presented on the endothelial surface which interact 
with CXCR3 on T cells leading to T cell arrest. At the same time, chemokine stimulation 
induces S1PR1/4 surface expression on T cells (3). T cell spreading and migration is 
supported by PGD2, generated through the metabolism of arachidonic acid (AA) by 
cyclooxygenases (COX), which operates through the PGD2 receptor, DP-2 (4) T cells spread 
and migrate across and through vascular endothelial cells. (5) Simultaneously, adherent B 
cells are simulated by circulating adiponectin through the AdipoR1/2 receptors, (6) resulting 
in the release of PEPITEM from B cells. (7) PEPITEM binds to Cadherin-15 (CDH15) on 
endothelial cells, stimulating the release of S1P from endothelial cells. (8) S1P binds to S1P 
receptors (S1P1/4) on recruited T cells, (9), which regulates the activation of the β2-integrin 
LFA-1 and inhibits trans-endothelial T cell migration. 
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ONLINE METHODS 
General. Alta Bioscience (University of Birmingham, Birmingham, UK) synthesized 
PEPITEM, scrambled peptide and biotinylated PEPITEM. We purchased Sphingosine-1- 
phosphate, W146 (trifluoroacetate salt), PGD2, SPHK1 inhibitor,2,2-dimethyl-4S-(1-oxo-2-
hexadecyn-1-yl)-1,1-dimethylester-3-oxazolidinecarboxylic acid, SPHK1 inhibitor 5c, and 
the SPK1/2 inhibitor, N,N-dimethylsphingosine from Cayman Chemicals (Michigan, USA). 
We purchased Chemokines and cytokines from Peprotech (London, UK) and R&D systems 
(Oxford, UK). 
 
Isolation of leukocytes. We obtained blood samples from healthy donors with written 
informed consent and approval from the University of Birmingham Local Ethical Review 
Committee (ERN_07-058). 
We isolated Peripheral blood mononuclear cells (PBMC) and neutrophils from blood using a 
two-step density gradient of Histopaque 1077 and 1119 (Sigma-Aldrich, Poole, UK). 
Lymphocytes were purified by panning PBMC on culture plastic for 30 minutes at 37°C to 
remove monocytes as previously described59. Peripheral Blood Lymphocytes (PBL) were 
then counted, resuspended in M199 (Life Technologies Invitrogen Compounds, Paisley, 
U.K.) containing 0.15% bovine serum albumin (BSA; Sigma-Aldrich) at 1x106 cells/ml for 
transmigration assays, or in PBS containing 0.5% BSA and 2 mM EDTA (Sigma-Aldrich) for 
cell sorting. B cells were depleted from PBL by positive selection using anti-CD19 beads 
(Miltenyi Biotec, Surrey, UK). When B cells were reconstituted into PBL or used to generate 
supernatants, B cells were sorted by negative selection in order to yield untouched cells 
(Stemcell, Grenoble, France). Memory and naïve CD4 and CD8 T cells were isolated using 
negative selection kits (StemCell). Monocytes and their subsets were isolated by positive 
selection using CD14 and CD16 beads (Miltenyi Biotec). 
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In vitro transmigration assay. Human umbilical cords were obtained from the Human 
Biomaterials Resource Centre (HBRC, University of Birmingham) (09/H1010/75) which 
holds ethical approval and collected fully consented tissue from the Birmingham Women’s 
Hospital NHS Trust. Human Umbilical Vein Endothelial cells (HUVEC) were isolated from 
umbilical cords as previously described60 and cultured in M199 supplemented with 20% FCS 
(Foetal Calf Serum), 10 ng/ml epidermal growth factor, 35 μg/ml gentamycin, 1 μg/ml 
hydrocortisone (all from Sigma-Aldrich), and 2.5 μg/ml amphotericin B (Life Technologies 
Invitrogen Compounds). Primary HUVEC were dissociated using trypsin/EDTA (Sigma-
Aldrich) and seeded on twelve-well tissue culture plates (Falcon; Becton Dickinson 
Labware), or iBidi chamber slides (iBidi, Martinsried, Germany) for adhesion assays in low 
serum medium 2% (Endothelial Basal Medium, Promocell, Heidelberg, Germany). Seeding 
density was chosen to yield confluent monolayers within 24 hours. TNF-α (100 U/ml; Sigma-
Aldrich) and IFN-γ (10 ng/ml; PeproTech, London, U.K.) were added to confluent 
monolayers for 24 hours before adhesion assay with lymphocytes. Primary human dermal 
endothelial cells (HDMEC) were purchased from Promocell and cultured in the 
manufacturer’s recommended medium (Edothelial cell growth medium) (Promocell,).  
HDMEC were used after four passages. 
Prior to adhesion assay, 1x106 PBL or 1x105 B cells were treated with adiponectin (0.0001 to 
15 μg/ml) at room temperature under agitation for one hour and washed prior to use. Static or 
flow based adhesion assays were performed as previously described18. EC were washed twice 
with M199 0.15% BSA to remove the excess cytokines. PBL were allowed to adhere to the 
EC for 6 minutes at 37°C before non-adherent cells were removed by washing with M199 
0.15% BSA. PBL adhesion and migration was assessed using a phase-contrast 
videomicroscope as previously described61. Manipulations and microscopy were carried out 
at 37°C. Recordings were digitized and analyzed offline using Image-Pro Plus software 
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(DataCell, Finchampstead, U.K.). The numbers of adherent cells were counted in each field, 
averaged and converted to cells per mm2 and multiplied by the known surface area of the EC 
monolayer to calculate the total number adherent. This number was divided by the known 
total number of PBL added to obtain the percentage of the PBL that had adhered. Each 
lymphocyte was classified as either: 1) phase bright and adherent to the surface of the EC; or 
2) phase dark and spread and migrating below the EC. The percentage of adherent 
lymphocytes that had transmigrated was calculated. In some experiments, data was 
normalized to the control by dividing the percentage transmigration of the treated sample by 
the percentage of transmigration of the control and multiplied by 100. 
 
For the B cell reconstitution experiments, B cells were negatively selected using StemSep 
magnetic kit and 100,000 cells incubated with 15 µg/ml adiponectin for one hour at room 
temperature. Cells were centrifuged 1500 rpm for 7 minutes and 1 ml of supernatant was 
added to 1x106 B cell-depleted PBL (1 B cell to 10 B cell-depleted PBL). Negatively sorted 
B cells (100,000) were incubated with Brefeldin-A (10 µg/ml) for 4 hours and adiponectin 
(15 µg/ml) for the last hour. Cells were then washed and supernatant added back to B cell 
depleted PBL and transmigration was measured.  
 
In some experiments, lymphocytes were pre-treated with 10 µM S1PR antagonist (W146) or 
S1P (0.0001 to 100 µM) at room temperature under agitation and washed after 30 minutes, so 
the treatments did not modulate HUVEC function. Alternatively, HUVEC or HDMEC were 
pre-treated with 5 µM of SPHK1 or SPHK1/2 antagonists at 37°C and washed after 30 
minutes. PEPITEM was added to the PBL or different leukocyte subsets at room temperature 
under agitation and washed after 30 minutes, so the treatments did not modulate HUVEC 
function, prior incubation of cells on EC.  
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 Firmly adhered PBL were collected from the EC surface using cold EDTA for 3 washes. 
Transmigrated PBL were collected by treatment of EC with accutase (Sigma-Aldrich). Both 
fractions were labelled and analyzed by flow cytometry as described below in the Flow 
cytometry section.  
 
Flow cytometry. PBMC were stained with the relevant antibodies for 30 minutes at 4°C. 
Subsequently, samples were labelled with the relevant secondary conjugated antibodies for 
30 minutes at 4°C. Isotype controls and secondary only conditions were used as negative 
controls. Rabbit anti-human AdipoR1 (357−375) and AdipoR2 (374−386) antibodies 
(Phoenix pharmaceuticals, Karlsruhe, Germany) were used at 5 µg/ml, and detected using a 
goat-anti rabbit Alexa 488 secondary antibody used at 8 µg/ml (Life Technologies Invitrogen 
Compounds). Gating to measure the expression of AdipoR1 and AdipoR2 on PBL and B 
cells was based on the isotype control. Isotype control frequencies were subtracted from the 
AdipoR1 and AdipoR2 frequencies for each subject. The following antibodies were used to 
stain human PBMC: CD4-FITC (1:50) (OKT-4), CD3-PerCp-Cy5.5 (1:50) (OKT3), CD19-
PECy7 (1:50) (HIB19), CD8-Pacific Blue (1:50) (OKT8), CD56-PE (1:50) (MEM188) (all 
from E-bioscience, Hatfield, UK), CD4-Pacific orange (1:10) (clone S3.5) (Life Technologies 
Invitrogen Compounds) and CD45RO-APC (1:20) (UCHL1) (BD Bioscience, Oxford, UK), 
α4β1-PE (1:100) (P5D2), αLβ2-FITC (1:100) (212701), DP-2-FITC (1:10) (301108) (R&D 
Systems, UK.), CXCR3-PE (1:50) (2Ar1) (US Biological). B cell subsets were labelled using 
CD19-PerCp-Vio700 (1:30) (LT19), IgM-PE (1:30) (PJ2-22H3), IgD-APC (1:60) (IgD26), 
CD38-FTIC (1:150) (IB6) and CD27-APC-Vio-770 (1:10) (M-T271) (all from Miltenyi 
Biotec).  
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The following antibodies were used to stain mouse PBMC from blood and peritoneal lavage: 
CD3-FITC (1:50) (145-2C11), CD3-PECy7 (1:50) (145-2C11), CD4-PB (1:100) (GK1.5), 
CD8-TR (1:200) (5H10), CD11C-PECy7 (1:50) (N418), CD19-APC (1:50) (1D3), CD44-
FITC (1:500) (IM7), CD45-PerCpCy5.5 (1:200) (30-F11), CD62L-PE (1:500) (MEL-14), 
B220-APCCy7 (1:100) (RA3-6B2), gp38-PE (1:200) (8.1.1) (all from Ebioscience) and 
F4/80-APC (1:20) (CI:A3-1) (AbD Serotec, Kidlington, UK). Samples were assayed using a 
Cyan (Dako) with Summit software and then analyzed using FlowJo software (Tree Star, 
Ashland, OR). Between 10,000 and 50,000 events per sample were recorded and plotted as 
frequency of positive cells or mean fluorescence intensity (MFI). 
 
Confocal Microscopy. Cells were grown to confluence onto glass chamber slides (Becton 
Dickinson Falcon) at 37°C. They were then fixed with 2% formaldehyde and 4% sucrose for 
15 minutes, washed in PBS and stained with 10 μg/ml of either a sheep anti-human CDH15 
antibody (Val22-Ala606) (R&D systems) or sheep IgG (Southern Biotech, UK) overnight at 
4 °C. Goat anti-sheep IgG1 conjugated to Alexa 488 (1:1000) (Abcam, UK) was then applied 
and the slides were visualized using a Zeiss LSM 510 inverted laser scanning confocal 
microscope using a X40 water immersion objective with excitation at 488 nm and 543 nm 
(Zeiss, Gottingen, Germany). Constant acquisition parameters and laser power were 
maintained throughout individual experiments for analysis and images were processed using 
Zeiss LSM Image Examiner software (Zeiss). Digital images were recorded in two separately 
scanned channels with no overlap in detection of emissions from the respective 
fluorochromes. Confocal micrographs were stored as digital arrays of 1024×1024 pixels with 
8-bit sensitivity.  
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Immunoprecipitation and Western Blotting. Whole cell lysates were extracted by 
suspending cells in lysis buffer with 50 mM Tris-HCl pH 8, 150 mM NaCl, 10% glycerol, 1% 
(w/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholate, and protease inhibitor cocktail 
(Invitrogen). After incubation for 15 minutes at 4 °C, this preparation was centrifuged at 
600 g for 10 minutes. The supernatant was subjected to immunoprecipitation by incubating 
for 30 minutes at 4oC with protein G-Dyna beads (Invitrogen) and polyclonal sheep anti-
CDH15 antibody (10 µg/ml) (Val22-Ala606) (R&D systems). The beads were collected and 
washed three times with ice-cold extraction buffer and once with 50 mM Tris-HCl pH 7.5. 
Proteins that were retained on the beads were eluted using 50 nM Glycine pH 2.8 and 
separated by SDS–PAGE 10% (w/v) and analyzed by western blot with a sheep anti-human 
CDH15 antibody (1 µg/ml) (Val22-Ala606) (R&D systems). Blots were then probed with 
appropriate horseradish peroxidase-conjugated anti-sheep secondary antibody (1:3000) (Cell 
Signalling Technology, UK). Immunodetection was carried out using the ECL plus Kit 
(Amersham, GE Healthcare Life Sciences, and UK) followed by exposure to X-ray film for 
15 minutes. Controls were run in parallel with application of the recombinant CDH15 (R&D 
systems). 
 
siRNA transfection. HUVEC were plated in 12 well plates (87,500 cells per well) for 24 
hours or until about 80% confluence. The relevant siRNA were added at a final concentration 
of 50 nM to 83.75 µl or 82.5 µl if duplex in Optimem media (Life Technologies Invitrogen 
Compounds). 1.5 µl of RNAi Lipofectamine (Life Technologies Invitrogen Compounds) was 
mixed with 13.5 µl of Optimem and incubated for 10 minutes at room temperature. 15 µl of 
Lipofectamine mix was added to each siRNA singleplex or duplex, gently mixed, and 
incubated for a further 10 minutes. HUVEC were washed twice with PBS and 400 µl of 
Optimem was added to the Lipofectamine siRNA duplexes. After gentle agitation, the mix 
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was added to the HUVEC and incubated at 37°C for 4 hours. The mix was then replaced with 
low serum media without antibiotics. After 48 hours, HUVEC were stimulated with TNF-α 
and IFN-γ for 24 hours before measuring PBL adhesion and migration as described 
previously. The PEPITEM receptor candidate was targeted by four siRNA oligomers that 
were purchased from Qiagen (Crawley, UK); CHD15 (#1: 
ATCGCCGACTTCATCAATGAT, #2: CACAGCCCTCATCTATGACTA, #3: 
CCCGATCAGCGTATCCGAGAA, #4: CAGGACGACCTTCGAGACAAT) and the S1P 
transporter SPNS2 (#1: CTGCACTTCTGCTGCAATCAA, #2: 
CCCACACAACTTGCTGGGCAA , #3: CAGCTTGGGCAACGTGCTCAA, #4: 
TGCCATTGGGACAATGAAGAA). Control random siRNA were purchased from 
ThermoScientific. 
 
Real-time PCR. Total mRNA was extracted using the RNAeasy Minikit (Qiagen, Crawley, 
UK) according to the manufacturer’s protocol. Briefly, PBMC were first lysed, then added to 
a column, after three washes, mRNA was eluted from the column with water. mRNA 
concentration was measured using Nanodrop spectrofluorimeter (LabTech) and mRNA was 
stored at −80°C. To convert mRNA to cDNA, random primers (Promega, Maddison, USA) 
were annealed to 1 µg of mRNA for 5 minutes at 70°C, after which the following mastermix 
was added to give a final volume of 30 µl: 10 U Superscript II Reverse Transcriptase (RT), 
10 U RNAout RNase inhibitor, 1X Superscript Buffer (all from Invitrogen) and 10 mM 
dNTPs (Promega). The reaction was run at 37°C for 1 hour, followed by 5 minutes at 95°C. 
To analyze mRNA, FAM-labelled SPHK1, SPHK2 and SPNS2 primers and VIC-labelled 
18S primers were bought as Assay on Demand kits from Applied Biosystems (Warrington, 
U.K.). Samples were amplified in duplicates using the 7500HT Real-Time PCR machine 
(Applied Biosystems) and analyzed using the software package SDS 2.2 (Applied 
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Biosystems). Data were expressed as relative expression units relative to 18S or as fold 
change (2^−deltadelta Ct method). 
 
Identification of PEPITEM. B cells (2x105−5x105) were incubated in presence or absence 
of adiponectin at 15 µg/ml. Adiponectin (15µg/ml) was added in M199 and used as a 
negative control. The peptides from the three samples were purified using C18 solid phase 
extraction columns from Supelco (DSC-18, Sigma-Aldrich). The columns were conditioned 
by adding 1ml of 0.1% trifluoroacetic acid (TFA, ThermoScientific) in acetonitrile (ACN, 
ThermoScientific), which like all additions was allowed to drip through the column under 
gravity. The column was then equilibrated with 0.1% TFA/water and the sample, adjusted to 
0.1% TFA, was added to the column. The column was washed with 1 ml of 0.1% TFA/water 
and the peptides eluted using 0.1% TFA/acetonitrile (1ml) which was dried under vacuum 
and the samples resuspended in 20 µl in 0.1% formic acid in 2% acetonitrile. 10 µl of the 
purified samples was subjected to a LC-MS/MS analysis using a gradient of 2−36% ACN in 
0.1% formic acid over 30 minutes at 350 nL/min using a Dionex Ultimate 3000 HPLC 
system. The HPLC column was connected to a Bruker ETD Amazon ion trap mass 
spectrometer with an online nanospray source.  An MS survey scan from 350 to 1600 m/z 
was performed and the five most intense ions in each survey scan were selected for CID 
(collision induced dissociation) fragmentation. After ions were fragmented twice they were 
placed on an exclusion list for 0.5 minute. The raw data was processed using the Bruker 
DatAnalysis peak detection program to select peaks which were then searched using the 
Mascot search engine (version  2.1) using the SwissProt protein database. The minimum 
mass accuracy for both the MS and MS/MS scans were set to 0.5 Da and no protease 
selection was used. The peptides were filtered using a minimum Mascot score of 30. The data 
output was analyzed via the Bruker ProteinScape software package. To identify a potential 
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candidate in the B cell supernatant with adiponectin treatment, we applied a subtractive data 
analysis method. Hits from the adiponectin stimulated sample were compared to the B cell 
supernatant without adiponectin and recombinant adiponectin controls and common analytes 
were discarded. The recombinant 14.3.3.ζδ protein (100 μg) (Fitzgerald industries 
international, Acton, US) was digested using trypsin at 40 µg/ml (in 10% ACN, 90% HPLC 
dH20, 0.1% TFA) for one hour at 37°C and samples were purified on C18 columns with at 
90% ACN and analyzed using MS and database search as previously described above. 
 
Identification of PEPITEM receptor. EC were incubated with an N-terminus biotinylated 
version of PEPITEM or biotinylated scrambled control for four hours at 4⁰C. Cells were then 
wash twice in cold PBS and lysed with a Triton phosphate buffer (20 mM Sodium phosphate 
pH 7.5, 150 mM NaCl, 1% Triton X100, Protease inhibitor, all from Sigma-Aldrich). After 
30 minutes, lysates were collected and centrifuged 20 minutes at 600 g at 4⁰C. Supernatants 
were collected and dried under vacuum and the samples resuspended in 20 µl 8 M Urea/2% 
SDS and loading buffer (Sigma-Aldrich and Life Technologies Invitrogen Compounds). 
Samples were loaded onto a 4−12% SDS-PAGE gel (Life Technologies Invitrogen 
Compounds) and stained overnight with Colloidal Coomassie staining buffer (0.08% 
Coomassie Brilliant Blue G250, 1.6% Orthophosphoric Acid, 8% Ammonium Sulphate, 20% 
Methanol, all from Sigma-Aldrich). Gels were detained in 1% Acetic acid in distilled water 
(several changes) until the background was clear. Protein bands were cut-out of the gel and 
washed twice in 50% Acetonitrile (ACN)/50 nM Ammonium Bicarbonate (AB, Sigma-
Aldrich) for 45 minutes at 37⁰C with agitation. The gel fragments were then incubated at 
56⁰C for 1 hour in 50 mM DTT in 10% ACN/50 mM AB then in 100 mM in 10% ACN/50 
mM AB for 30 minutes at room temperature in the dark. Bands were washed twice in 10% 
ACN/40 mM AB for 15 minutes and dried under vacuum until completely dry. Trypsin 
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(Promega, Southampton UK) was then added on the bands at 200 µg/ml in 10% ACN/40 mM 
AB and left overnight at 37⁰C. Supernatant was then collected and bands were washed twice 
in 3% Formic acid for 1 hour at room temperature under agitation. Supernatants were 
collected and pooled together after all washes and samples were dried under vacuum, 
resuspended in 20 µl in 0.1% formic acid in 2% ACN. 10 µl of the purified samples was 
subjected to an LC-MS/MS analysis using a gradient of 2−36% ACN in 0.1% formic acid 
over 30 minutes at 350 nL/min using a Dionex Ultimate 3000 HPLC system, as already 
described in the section: Identification of PEPITEM.  
 
Biacore assay. All Biacore was performed with the help of Dr. Catherine McDonnel (GE 
Healthcare) using a BiacoreTM T200 system (GE Healthcare). To test peptide binding to 
CDH15, recombinant CDH15-Fc (50 μg/ml) (R&D Systems) was immobilized on protein A 
bound to a chip using a standard protocol (900s, 5 μl/min). N-terminal biotinylated PEPITEM 
(24 µg/ml to 770 µg/ml) in HBS-P buffer (GE Healthcare), 5mM CaCl2 and 0.05%P20 was 
flowed over the chip at a flow rate of 30 µl/min for 60s injection and 600s dissociation. For 
this experiment, Buffer alone and random peptides were used as controls in case of any non-
specific binding, as well as scrambled biotinylated PEPITEM. Binding kinetics were 
measured in response units (RU) and ‘BiaEvaluation’ software was used to analyze the data 
traces. 
 
Quantification of PEPITEM. 500,000 negatively selected B cells were incubated in the 
presence or absence of adiponectin 15 μg/ml for 1 hour at room temperature. After 
centrifugation at 250 g for 7 minutes, supernatants were ‘spiked’ with 10 ng 3H (tritium) 
radiolabelled PEPITEM as an internal mass standard for relative intensity quantification. 
Peptides were purified on DSC-18 solid phase extraction columns as described above and 
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analyzed by LC-MS/MS as described above. Due to their identical chromatographic 
properties, endogenous and synthetic radiolabelled versions of PEPITEM elute at the same 
point on the gradient, allowing comparison in the same mass spectrum. However, due to their 
different physical properties, these versions are readily resolved as separate peaks within this 
mass spectrum. Therefore, extracted ion chromatograms (EIC) comparing intensity of the 10 
ng radiolabelled standard (m/z 780.88±0.05) to that of endogenous PEPITEM (m/z 
774.88±0.05) allowed quantification of the native peptide. This method of relative intensity 
quantification is time-honoured within the field of analytical science62.  
 
Alternatively, B cell subsets were isolated by automated cell sorting using a Moflow Astrios 
EQ (Beckman Coulter) and labelled as previously described in the section: In vitro 
transmigration assay. The B cell subsets were then incubated with 15 μg/ml of adiponectin 
for one hour. Supernatants were collected and analyzed by mass spectrometry to quantify 
PEPITEM using the radiolabelled quantification method. 
 
Samples for the PEPITEM secretion time-course were collected after 5, 15, 30 minutes, 1, 3 
and 24 hours after PEPITEM incubation on endothelial cells. Samples were centrifuged, 
purified on C18 columns at 100% ACN and analyzed by MS using the radiolabelled 
quantification method. 
 
Identifying changes in the affinity of αLβ2 on lymphocytes. 96 well plates were coated 
with 50 ug/ml of recombinant ICAM-1/Fc (R&D Systems) overnight at 4⁰C. The plate was 
blocked using PBS 2% BSA for an hour at room temperature and PBL treated with CXCL10 
(80 ng/ml) and/or S1P (10 uM) were added for 6 minutes. Excess of unbound PBL was 
washed away. Bound PBL were collected using cold PBS by rough pipetting and PBL were 
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labelled at 4 ⁰C for the lymphocyte integrin αLβ2 (LFA-1) using the mouse anti-human 
KIM127 (10 μg/ml) antibody recognizing the intermediate affinity epitope (Nancy Hogg, 
London) or the S1PR1 antibody (5 μg/ml; Cayman chemicals; amino acids 241−253 
(ISKASRSSEKSLA)). KIM127 was detected using a goat anti-mouse Alexa 488 secondary 
antibody (Invitrogen) at 8 µg/ml and S1PR1 with a donkey anti-rabbit Alexa 488 secondary 
antibody (Invitrogen) at 8 µg/ml. The expression of the affinity site was measured on 
memory T cells (CD45RO+ CD3+ T cells) by flow cytometry as described in the section: 
Flow cytometry. To measure the expression of S1PRs on firmly adhered and transmigrated 
memory T cells, we washed the endothelial cells after 6 minutes of PBL transmigration using 
cold EDTA (Sigma-Aldrich). The EDTA wash was repeated until all firmly adhered cells 
were recovered. Transmigrated cells were collected with endothelial cells using accutase for 
one minute at 37°C and firmly adhered and transmigrated cells were labelled with CD45RO-
APC (1:20) (UCHL1) (BD Bioscience) and CD3-PerCp-Cy5.5 (1:50) (OKT3) 
(Ebioscience)  and S1PR1 and analyzed by flow cytometry. 
 
Investigating the function of PEPITEM in mouse models of inflammation. 
All experiments were performed in accordance with United Kingdom Home Office 
regulations. For the animal studies, in each experiment B cell-deficient or wild-type (WT) 
animals with the same background were allocated at random to different experimental 
groups. Importantly, mice from the same litter were randomly distributed amongst the 
experimental groups and where possible, were equally distributed amongst experimental 
groups. Comparison of peptide, scrambled peptide, and carrier (PBS) were carried out on the 
same day with identical reagents when possible.  
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Acute peritoneal inflammation. BALB/c WT or BALB/c B cell-deficient mice (Igh−Jtm1Dhu 
N?+N2, these mice carry a deletion of the J segments of the Ig heavy chain locus) (Taconic, 
New York, USA) were housed in the Biomedical Services Unit at the University of 
Birmingham. Mice were used between 6 and 8 weeks of age and were matched for sex as 
both male and females were used. Peritonitis was induced by the intraperitoneal injection 
(i.p) of 1 mg of type A zymosan (Sigma-Aldrich) as previously described63. In some animals 
zymosan was delivered with 300 μg PEPITEM or scrambled peptide. Cells washed from the 
peritoneal cavity were collected in PBS at 48 hours post injection. Erythrocytes in the 
peritoneal exudates were lysed and leukocytes stained for analysis by flow cytometry. Tubes 
containing the cells from the peritoneal exudates were fully acquired on the flow cytometry to 
accurately count the cells. Gates were set up on all cells in the peritoneum and the number of 
T cells was determined based on CD3 expression. Blood was drawn by cardiac puncture 
under the armpit and processed as for peritoneal exudate cells. All data was normalized to the 
number of T cells in WT mice treated with zymosan. 
 
Systemic bacteraemia upon Salmonella infection in the liver. For Salmonella infections, 
attenuated Salmonella Typhimurium (strain SL3261, originally obtained from Dr RA 
Kingsley (Wellcome Trust Sanger Institute, Cambridge64) was grown overnight and bacteria 
were harvested from log phase cultures as described previously65. C57BL/6 WT or C57BL/6 
B cell-deficient (B cell-deficient mice were generated in house from breeding out the QM 
(quasi-monoclonal) IgH transgene from QM mice, which have the other IgH locus 
inactivated)66 mice were infected by intraperitoneal injection with 5 x 105 S. Typhimurium in 
PBS containing 100 µg PEPITEM. Mice were used between 6 and 8 weeks of age and were 
matched for sex as both male and females were used. Control mice received 5x105 S. 
Typhimurium in PBS only. Mice received further PEPITEM (or PBS) injections (100 µg i.p.) 
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daily for the next 4 days and all samples were collected at day 5 or 7 post-infection. Livers 
were immediately frozen and were subsequently examined by immunohistochemistry (IHC) 
as has been described elsewhere67. All IHC was performed in Tris buffer (pH 7.6) at room 
temperature. Primary antibodies specific for CD3 (1:300) (145-2C11, BD Pharmingen) and 
F4/80 (1:500) (Cl:A3:1, AbD Serotec), and secondary antibodies (Dako Cytomation) (horse-
radish peroxidase- (1:300) or biotin-conjugated (1:600)) were added for 60 and 45 minutes 
respectively. Slides were developed using 3, 3’-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich) or alkaline-phosphatase (ABComplex, Vector Laboratories) and levamisole with 
napthol AS-MX phosphate and Fast Blue BB salt (all from Sigma-Aldrich) respectively. 
Slides were mounted in glycerol (Sigma-Aldrich) and images acquired using a Leica 
CTR6000 microscope (Leica, Milton Keynes, UK) with Image J and QCapture software. 
Mean CD3+ cells per foci were quantified for a minimum of 50 foci per tissue section at x25 
magnification. 
 
Acute liver ischemia and reperfusion injury. Splenic T cells were isolated from 8−10 week 
old male C57BL/6 WT mice (Harlan, Oxford, UK) through negative selection magnetic 
activated cell sorting (MACS) using the Pan T cell isolation kit II (Miltenyi Biotec, Surrey, 
UK) according to the manufacturer’s instructions.  C57BL/6 mice were anesthetised by 
intraperitoneal injection of ketamine (100 mg/Kg, Vetlar V, Phizer, Kent, UK) and xylazine 
hydrochloride (10 mg/Kg, Xylacare, Animalcare, York, UK) delivered in 0.9% saline 
solution.  The trachea and right common carotid artery were cannulated and the liver was 
exposed. Prior to ischemia, 250 µl of PEPITEM or scrambled peptide was injected via the 
carotid artery and allowed to circulate for 5 minutes.  Ischemia of the left and median lobes of 
the liver was induced through application of a traumatic vascular clamp to the hepatic artery 
and portal vein supplying these lobes for 90 minutes. After 90 minutes of ischemia the clamp 
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was removed and intravital observations carried out. Using an Olympus IX81 inverted 
microscope (Olympus, UK) the microvasculature of the liver was viewed through a 10X 
objective.  1 million fluorescently labelled T cells (CFDA-SE, 10 µM, Life Technologies, 
Paisley, UK) with 20 µl of PEPITEM/scrambled peptide were injected into the carotid artery 
at the point of clamp removal. A random field was selected every 10 minutes and imaged for 
20 seconds. Five additional fields of view in a pre-defined pattern were then imaged for 20 
seconds each. Adherent cells were defined as cells that were static for at least 20 seconds. 
Cells were counted on each field. 
 
Acute model of LPS (Lipopolysaccharide) driven uveitis (EIU-experimental autoimmune 
uveitis). C57BL/6J WT mice were originally obtained from Harlan UK Limited (Oxford, 
U.K.), and breeding colonies were established within the Animal Services Unit at Bristol 
University (Bristol, U.K.). Mice were housed in specific pathogen-free conditions with 
continuously available water and food. Female mice immunized for disease induction were 
aged between 6 and 8 weeks. All mice were kept in the animal house facilities of the 
University of Bristol. Treatment of animals conformed to United Kingdom legislation and to 
the Association for Research in Vision and Ophthalmology statement for the Use of Animals 
in Ophthalmic and Vision Research. 
 
EIU Induction and therapeutic intervention 
Local administration of LPS from Salmonella Typhimurium (50ng/eye) (Sigma-Aldrich) was 
performed by intravitreal injection in anesthetised B6LY5 mice as previously described68.  
Animals were anesthetised by i.p injection of 150 μl of Vetalar (ketamine hydrochloride 
100mg/ml; Pfizer, Sandwich, UK) and Rompun (xylazine hydrochloride 20mg/ml; Bayer, 
Newburg, UK) mixed with sterile water in a ratio of 0.6:1:84.  The pupils of all animals were 
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dilated using topical tropicamide 1% (Minims from Chauvin Pharmaceuticals Ltd, UK).  
Intravitreal injections were performed under the direct control of a surgical microscope with 
the tip of a 12 mm 33-gauge hypodermic needle mounted on a 5 μl syringe (Hamilton AG, 
Bonaduz, Switzerland).  For treatment groups either PEPITEM (6 µg) or PBS were combined 
with 50ng/eye of LPS as a single injection, administered in a total volume of 4 μl per 
injection.  The injection site was treated with chloramphenicol ointment. 
 
Isolation of ocular infiltrate 
At 15 hours following LPS/treatment administration, eyes were enucleated and carefully 
cleaned to remove all extraneous connective and vascular tissue.  The aqueous & vitreous 
humour, iris, ciliary body and retina were microscopically dissected in HBSS (Life 
Technologies, Paisley, UK).  These ocular components were homogenized and forced 
through a 70 µm cell strainer with a syringe plunger, to obtain a single-cell suspension, and 
stained for flow cytometry analysis. 
 
Flow cytometric analysis of ocular infiltrate 
Cells were incubated with 24G2 cell supernatant for 10 minutes at 4oC before incubation with 
fluorochrome-conjugated monoclonal antibodies (all from BD Bioscience, Oxford, UK) 
against cell surface markers CD45 (1:1000) (30-F11), CD4 (1:100) (RM4-5) and CD8 
(1:100) (53-6.7) at 4oC for 20 minutes.  Cells were resuspended in 7-aminoactinomycin D 
(7AAD) (Molecular Probes), and dead cells were excluded from analysis by gating on 7AAD 
negative cells.  Measurement of cell suspensions were acquired using a three-laser BD LSR-
II flow cytometer (BD Cytometry Systems, Oxford, UK) and analyzed was performed using 
FlowJo software version 7.6.5 (Tree Star, Ashland, OR).  Cell numbers were calculated by 
reference to a known cell standard, as previously reported64.  Briefly, splenocytes at a range 
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of known cell concentrations were acquired using a fixed and stable flow rate for 1 minute.  
Based on total cell number acquired during this time, a standard curve was generated and 
used to interpolate cell concentrations of ocular infiltrating cells acquired at the same flow 
rate and time. 
 
Virally induced Sjögren’s syndrome. 
Mice and salivary gland cannulation.  
C57BL/6 mice were from Harlan. Under ketamine-domitor (Pfizer, Sandwich, UK) 
anesthesia, the submandibular glands of female C57BL/6 mice (8−12 weeks old) were 
intraductally cannulated with 108−109 pfu of luciferase-encoding replication-defective 
adenovirus (AdV5), as previously described40. A group of 5 mice were administered (i.p 
injections) 100 μg PEPITEM and another group of 5 mice were administered 100 μg 
scrambled peptide every day until day 5 post-cannulation (p.c.). 
 
Histology and Immunofluorescence.  
Salivary glands from cannulated mice treated with PEPITEM and scrambled peptides were 
harvested, snap frozen in OCT (Sakura, UK) over liquid nitrogen. Frozen sections of 7 μm in 
thickness were cut, left to dry overnight at room temperature, next day they were stored in 
−80°C until use. For immunofluorescence analysis, slides were allowed to come to room 
temperature and then fixed for 20 minutes in ice-cold acetone, left to dry and then were 
hydrated in PBS. For immunofluorescence staining, all dilutions of reagents and antibodies 
were made in PBS with 1% BSA. Firstly, to block endogenous biotin sections were treated 
with 0.05% avidin (Sigma-Aldrich)  and 0.005% biotin (Sigma-Aldrich) for 15 minutes each 
and a washed for 5 minutes with PBS in between the two incubations. Followed by, blocking 
with 10% horse serum (Sigma-Aldrich) for 10 minutes. Slides were then incubated for 60 
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minutes with ‘cocktails’ containing the following primary antibodies in PBS (1% BSA); 
CD19 Alexa Fluor647 (1:50) (eBio1D3), CD3ε biotin (1:50) (ebio500A2) (both were from 
Ebioscience). Biotinylated CD3ε was detected using streptavidin-Alexa Fluor 555 (1:500) 
(Molecular Probes). Hoescht (1:1000) (Molecular Probes) was used for nuclear stain. All 
secondary antibodies were incubated for 30 minutes. Slides were mounted with Prolong Gold 
Antifade reagent (Life Technologies).  
 
Images were acquired on a Zeiss 780 upright confocal head with a Zeiss Axio Imager Z1 
microscope and viewed through a 10X objective. Digital images were recorded in three 
separately scanned channels with no overlap in detection of emissions from the respective 
fluorochromes. Confocal micrographs were stored as digital arrays of 1024×1024 pixels with 
8-bit sensitivity; detectors were routinely set so that intensities in each channel spanned the 
0−255 scale optimally. The Zen 2010 Software was used to process these images. 
 
Isolation of leukocytes.  
Cannulated salivary glands were harvested and chopped into small pieces and digested for 20 
minutes at 37°C with gentle stirring in 2 ml RPMI 1640 medium (Sigma-Aldrich) containing 
collagenase dispase (250 μg/ml; from Roche, Welwyn, UK), DNAse I (25 μg/ml; from 
Sigma-Aldrich) and 2% (vol/vol) FCS. The suspension was gently pipetted to break up 
aggregates. During the final pipetting, EDTA (Sigma-Aldrich) was added to a final 
concentration of 10 mM to further reduce cell aggregates. Cells were then passed through a 
70 μm mesh with a syringe, were washed twice and resuspended in PBS (with 0.5% BSA and 
2 mM EDTA) 
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Flow cytometry.  
Single cells suspensions were stained for 30 minutes in PBS (with 0.5% BSA and 2 mM 
EDTA) with ‘cocktails’ of the following antibodies CD3ε PECy7 (1:200) (145-2C11), CD19 
APC-Cy7 (1:100) (eBio1D3) (from EBiosciences). Cells were then washed twice in PBS 
(with 0.5% BSA and 2 mM EDTA), resuspended in PBS (with 0.5% BSA and 2 mM EDTA) 
and then analyzed using a Cyan-ADP (Dako) with forward/side scatter gates set to exclude 
non-viable cells. Data were analyzed with FlowJo software (Tree Star, Oregon, USA).  
 
Patient studies. Sample size for the patient studies were guided by the variance from a 
previous study in our laboratory in which we determined the frequency of adiponectin 
receptors on monocytes from individuals with T1D versus matched healthy controls7. 
Randomization was not required for this study. All patients and controls were analyzed in 
parallel on the same flow cytometer over a period of weeks, as they became available from 
clinic. The expression of the adiponectin receptors was always determined compared to the 
isotype control for each sample. The same batch numbers of flow cytometry reagents was 
used throughout to ensure standardisation and reduce inter-experimental variation. 
 
T1D. Individuals with T1D were recruited from University Hospital Birmingham Department 
of Diabetes outpatient clinics. Individuals had received a diagnosis of T1D fulfilling the 1999 
WHO framework65. Blood samples were obtained with written informed consent and 
approval from the Birmingham, East, North and Solihull Research Ethics Committee 
(06/Q2703/47). 
Healthy volunteers were matched to the T1D cohort on gender, age and BMI (Clinical 
parameters in Supplementary Table 6 and 7). AdipoR1/2 expression on B cells was 
measured in 19 healthy controls (58% males) and 29 individuals with T1D (65% male).  
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Quantification of PEPITEM secretion by B cells under adiponectin stimulation was measured 
in 10 healthy controls (60% males) and 10 individuals with T1D (60% males). Lymphocyte 
transmigration was measured for 15 healthy controls (55% males) and 9 (for the PEPITEM 
cohort) or 22 (for the adiponectin cohort) individuals with T1D (60% males).  
 
Rheumatoid arthritis. Individuals with rheumatoid arthritis were recruited from the 
Birmingham Early Arthritis Cohort (BEACON). Rheumatoid arthritis was classified 
according to 1987 American College of Rheumatology criteria. Blood samples were obtained 
with written informed consent and approval from the NRES committee West Midland, the 
Black Country (2/WM/0258). Healthy volunteers were matched to the rheumatoid arthritis 
cohort on gender and age (Clinical parameters in Supplementary Table 8). AdipoR1/2 
expression on B cells was measured in 10 healthy controls (30% males) and 12 individuals 
with rheumatoid arthritis (41% males). Lymphocyte transmigration was measured for 7 
healthy controls (57% males) and 8 individuals with rheumatoid arthritis (12.5% males).  
Ageing study. AdipoR1/2 expression on B cells was measured in 40 healthy volunteers 
ranging in age from 21 to 66 years old. 
 
Statistics. In vitro data are from at least 3 experiments including 3 separate donors for PBL, 
HUVEC or HDMEC and are the mean of these different experiments ± s.e.m or SD as stated. 
Numbers of animals in each model are stated in the figure legends. The number of individuals 
with T1D or RA, or healthy controls compared is stated in the figure legends. Differences 
were analyzed using GraphPad Prism software (GraphPad software Inc., LaJolla, USA) by 
paired or unpaired t-test or by one way ANOVA followed by post hoc analysis for multiple 
group comparison (Dunnett or Bonferroni). A Dunnett post hoc analysis was used to compare 
all the data sets on the graph to a common control. A Bonferroni post hoc test was used to 
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compare all data sets in a graph with each other. Normality was checked using the 
Kolmogorov-Smirnov test. A non-parametric test (Mann-Whitney test) was used when data 
did not pass the normality test. The Wilcoxon signed rank test was used to compare a data set 
to a normalized control, where the data was presented as a percentage of that control (i.e. 
where control values were the same, e.g 100%). P values ≤ 0.05 were considered significant. 
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